U.S. pharma giant copyright scrapped two experimental weight loss tablets last 12 months—a when-daily capsule, lotiglipron, as a result of elevated liver enzymes in addition to a 2 times-day-to-day capsule, danuglipron, resulting from potent Negative effects—but CEO Albert Bourla has